Fallopian Tube Cancer Clinical Trials in Pittsburgh, Pennsylvania
9 recruitingPittsburgh, Pennsylvania
Showing 1–9 of 9 trials
Recruiting
Phase 3
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Stage III Ovarian CancerStage IV Ovarian CancerStage III Fallopian Tube Cancer+3 more
GOG Foundation220 enrolled59 locationsNCT05659381
Recruiting
Phase 2
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Ovarian CancerEndometrial CancerFallopian Tube Cancer+1 more
Corcept Therapeutics270 enrolled49 locationsNCT06906341
Recruiting
Phase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Regeneron Pharmaceuticals220 enrolled50 locationsNCT06787612
Recruiting
Phase 2
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
Fallopian Tube CancerOvary CancerPeritoneal Cancer
University of Colorado, Denver53 enrolled5 locationsNCT05887609
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Endometrial CancerPrimary Peritoneal CarcinomaNon-small Cell Lung Cancer+6 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting
Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
AbbVie520 enrolled264 locationsNCT05445778
Recruiting
Phase 1
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Primary Peritoneal CarcinomaFallopian Tube CancerEpithelial Ovarian Cancer
Regeneron Pharmaceuticals90 enrolled5 locationsNCT06469281
Recruiting
Phase 2
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Advanced High-Grade Epithelial OvarianPrimary PeritonealFallopian Tube Cancers+2 more
AbbVie110 enrolled37 locationsNCT06682988
Recruiting
Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Alexander B Olawaiye, MD33 enrolled1 locationNCT05071937